Prism Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 12-12-2024
- Paid Up Capital ₹ 1.00 M
as on 12-12-2024
- Company Age 22 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.12 Cr
as on 12-12-2024
- Satisfied Charges ₹ 0.24 M
as on 12-12-2024
- Revenue -10.09%
(FY 2017)
- Profit -191.52%
(FY 2017)
- Ebitda -102.38%
(FY 2017)
- Net Worth -10.36%
(FY 2017)
- Total Assets -7.16%
(FY 2017)
About Prism Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.12 Cr. The company has closed loans amounting to ₹0.24 M, as per Ministry of Corporate Affairs (MCA) records.
Ramalingam Lakshmi and Ramalingam Jayaram serve as directors at the Company.
- CIN/LLPIN
U24231TN2002PTC049597
- Company No.
049597
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Sep 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Prism Pharma (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramalingam Lakshmi  | Director | 13-Sep-2002 | Current |
| Ramalingam Jayaram | Director | 21-Sep-2017 | Current |
Financial Performance of Prism Pharma (India).
Prism Pharma (India) Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 10.09% decrease. The company also saw a substantial fall in profitability, with a 191.52% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prism Pharma (India)?
In 2017, Prism Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 12 Dec 2022 | ₹0.90 M | Open |
State Bank Of India Creation Date: 16 Sep 2020 | ₹0.59 M | Open |
State Bank Of India Creation Date: 09 Aug 2004 | ₹9.60 M | Open |
How Many Employees Work at Prism Pharma (India)?
Unlock and access historical data on people associated with Prism Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prism Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prism Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
